Viz.ai operates an AI-powered platform that identifies patients, informs critical decisions at the point of care, and coordinates radiologists, emergency physicians and specialists to optimize care pathways. The platform is backed by clinical evidence and is used to increase speed of diagnosis and access to life-saving treatments. Viz.ai serves a patient every 21 seconds and covers more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The company plans to expand its end-to-end platform into new disease areas and evaluate strategic acquisition opportunities. Viz.ai recently received growth capital financing to support that expansion and continued product development. The business is supported by a roster of venture investors that have previously backed the company. Viz.ai provides an AI-driven platform that delivers synchronized care coordination, high-fidelity mobile image viewing, automated workflows, and computational diagnostics to connect radiologists, emergency physicians, and primary care practitioners with specialists. The company pioneered stroke detection and triage with a de novo FDA clearance and was the first AI software to receive CMS NTAP approval. Viz.ai has expanded its platform into additional disease states (aortic disease, pulmonary embolism, cerebral aneurysms) and is 510(k) pending for subdural hematoma, and it launched a life-science platform to support clinical trials. The Viz Platform is used in more than 1,000 hospitals across the US and EMEA, has assisted millions of patients, and the company says it assists in the care of one patient every 32 seconds. The business is growing rapidly: headcount rose from 180 to more than 350 over the past 12 months and the company plans to hire nearly 200 more in the next 12 months. Viz.ai lists customers including Mount Sinai, Thomas Jefferson University, Banner Health, CommonSpirit Health, and HCA Healthcare, and operates from offices in San Francisco, Tel Aviv, Portugal, and Amsterdam. Viz.ai’s core product is an AI-powered Intelligent Care Coordination platform, with flagship offering Viz LVO that detects large vessel occlusions and routes time-sensitive information to specialists. The platform includes automated alerts and triage, mobile DICOM image viewing, HIPAA-compliant messaging, and point-of-care consults. Viz LVO has multiple FDA clearances (De Novo in 2018; additional clearances for Viz CTP and Viz ICH) and received the first CMS NTAP for AI software; a multi-center real-world study reported a median time-to-notification of 5 minutes 45 seconds and achieved 96% sensitivity and 94% specificity across 2,544 consecutive patients from 139 hospitals. The company plans to expand the platform beyond stroke into other acute care specialties such as cardiology, pulmonary and trauma, and to enter new global markets. Viz.ai says its technology improves triage, patient outcomes, and economics for health systems by reducing time to treatment and preventing care breakdowns. The company is based in San Francisco and Tel Aviv and positions its product as clinically validated and commercially reimbursed in relevant cases. Viz.ai builds synchronized healthcare software (Viz) that leverages deep learning to identify suspected large vessel occlusions (LVO) on CT scans and notify stroke specialists to speed treatment. Its flagship product, Viz LVO, routes time-sensitive information to clinicians in minutes to synchronize care and reduce time to treatment. In February 2018 the FDA granted De Novo clearance for Viz LVO; the company later received 510(k) clearance for Viz CTP for automated cerebral perfusion analysis. Viz.ai’s acute ischemic stroke software is deployed in over 300 U.S. hospitals and is credited with shortening time to treatment and increasing the number of patients able to receive lifesaving therapy. Management says the company will use the new funding to expand Synchronized Care to additional disease states and geographies to democratize quality of care globally. The company positions its platform to curate expanding healthcare data and make it immediately actionable for providers, aiming to reduce costs and support value-based care. Viz.ai develops a cloud-based AI platform that analyzes brain CT scans to detect large vessel occlusions and alerts neurovascular specialists to speed treatment. Its flagship product, Viz LVO, was granted FDA De Novo clearance and the company also received FDA 510(k) clearance for Viz CTP. The platform uses deep learning to automate triage and is designed to integrate with existing emergency-room workflows. Viz.ai says the software delivers alerts in minutes to facilitate early therapeutic intervention and improve access to proven therapies. The company will use the $21 million Series A to expand market reach and to extend its product portfolio beyond stroke. Founded in 2016 and based in San Francisco and Tel Aviv, Viz.ai is backed by Kleiner Perkins, GV, Innovation Endeavors and DHVC.

Total raised

$290M

Funding rounds

6

Latest round

Equity

Latest activity

Mar 2023